Madrid, Spain (ots/PRNewswire)
- Zeltia S.A, the Spanish consumer
chemicals and biotechnology group announces today that its Board of
Directors has authorized a capital increase through a private
placement with qualified international institutional investors.
The capital increase is expected to raise approximately one
hundred (100) million euros. A "green shoe" of up to 15% of the
amount raised can be exercised by HSBC, which is the Sole Bookrunner
on the transaction.
The funds raised will be used to further the continued
research, development and commercialisation of cancer products being
developed by PharmaMar, Zeltia's biotech subsidiary.
The capital increase will be made through an Accelerated Bookbuilt
Offering (ABO) to qualified institutional investors and will close on
Wednesday 22 June, when the price will be fixed and the shares
C/ Reyes, 1.Colmenar Viejo
Head of Capital Market Strategy
José Abascal , 2
Corporate Communications Director
Zeltia , S.A.
José Abascal ,2
This announcement does not, and shall not, in any circumstances
constitute a public offering nor an invitation to the public in
connection with any offering.
This announcement does not constitute or form part of any offer or
solicitation to purchase or subscribe for securities in the United
States or by U.S. Persons (as defined in Regulation S under the
United States Securities Act of 1933, as amended (the "Securities
Act")). The securities mentioned herein have not been, and will not
be, registered under the Securities Act. They may not be offered or
sold in the United States or to, or for the account or benefit of
U.S. persons, except pursuant to an exemption from the registration
requirements of the Securities Act. No public offer of the securities
is being made in the United States.
In the United Kingdom, this announcement is for distribution only
to investment professionals, high net worth companies, partnerships,
associations or trusts and investment personnel of any of the
foregoing (each within the Financial Services and Markets Act 2000
(financial promotion) Order 2001) and any other persons to whom it
may be communicated lawfully. The securities specified in this
announcement may be subscribed exclusively by such persons. No other
person should act or rely on it. Persons distributing this press
release must satisfy themselves that it is lawful to do so.
A folleto informativo has been registered with Spain's Comision
Nacional del Mercado de Valores and offers of the securities
mentioned herein can be made in Spain in accordance with applicable
Spanish law and regulations and the terms of the folleto informativo.
The distribution of this announcement in certain countries may
constitute a breach of applicable law.
PharmaMar is a biopharmaceutical company pioneer in the discovery
and development of novel anticancer drugs derived from marine
organisms. PharmaMar's clinical portfolio currently includes five
compounds: Yondelis in Phase II/III trials for solid tumours
(co-developed with Johnson & Johnson Pharmaceutical Research &
development), designated Orphan Drug for STS and Ovarian cancer by
the European Commission (EC) and the FDA. Yondelis is being developed
as a single agent and in combination therapy. Aplidin in Phase II for
solid and haematological tumours, designated Orphan Drug for acute
lymphoblastic leukaemia and for multiple Myeloma by the FDA and the
CE. Kahalalide F in Phase II for solid tumours and severe psoriasis.
ES-285 and Zalypsis in Phase I trials for solid tumours.
Zeltia S.A. is the pioneer biotechnology company in Spain with a
market capitalization of around 1.2 billion euros. The group is
comprised of the following subsidiaries: PharmaMar, founded in 1986,
a biopharmaceutical company devoted to the discovery and development
of novel anticancer drugs derived from marine organisms. Neuropharma
devoted to the discovery and development of novel drugs against
Alzheimer's and other degenerative diseases of the central nervous
system; Genomica which produces and sells DNA diagnostic tools; and
Zelnova and Xylazel, two very profitable companies that build on
Zeltia's heritage in the chemical business.
ots Originaltext: Zeltia Group and PharmaMar
Im Internet recherchierbar: http://www.presseportal.ch
Isabel Lozano, CEO, PharmaMar S.A., Tel: +34-91-846-60-00; Catherine
Moukheibir, Head of Capital Market Strategy, Zeltia , S.A., Tel:
+34-91-444-45-00; Coro Egaña, Corporate Communications Director,
Zeltia , S.A., Tel: +34-91-444-45-00